An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

Arthritis and Rheumatism

Volumn 63, Issue 2, 2011, Pages 337-345

  Genovese, Mark C ^a   Kavanaugh, Arthur ^b   Weinblatt, Michael E ^c   Peterfy, Charles ^d   Dicarlo, Julie ^e   White, Michael L ^f   O'Brien, Maryann ^g   Grossbard, Elliott B ^g   Magilavy, Daniel B ^g  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Spire Sciences LLC   (United States)

^e SYNARC INC   (United States)

^f Kendle Research Associates   (United States)

^g RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FOSTAMATINIB; PLACEBO; PROTEIN KINASE SYK INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYNOVITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ENZYME INHIBITORS; FEMALE; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JOINTS; MALE; MIDDLE AGED; OXAZINES; PRODRUGS; PROTEIN-TYROSINE KINASES; PYRIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650294662     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30114     Document Type: Article

References (14)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
2. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 1114-23.
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
4. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [published erratum appears in Ann Rheum Dis 2009;68:296]. Ann Rheum Dis 2008; 67: 1516-23.
5. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al, GO-AFTER Study Investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial [published erratum appears in Lancet 2009;374:1422]. Lancet 2009; 374: 210-21.
6. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006; 317: 571-8.
7. Pine P, Chang B, Schoettler N, Banquerigo M, Wang S, Lau A, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007; 124: 244-57.
8. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 3309-18.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
10. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
11. Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003; 30: 1385-6.
12. McQueen FM, Gao A, Ostergaard M, King A, Shalley G, Robinson E, et al. High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone. Ann Rheum Dis 2007; 66: 1581-7.
13. Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, et al, and the CIMESTRA Study Group. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis: results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68: 384-90.
14. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB,. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363: 1303-12.